GK
GKOS.US Glaukos Corp
- Market cap
- USD 14.5B
- P/E
- -
- P/B
- 20.30x
- ROE
- -6.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GKOS.US undervalued?
Graham numberThe Graham number of Glaukos Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Glaukos Corp fundamental analysis
No fundamental analysis for Glaukos Corp yet.
Glaukos Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the…
Full company profileGlaukos Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Glaukos Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 114M | 159M | 181M | 237M | 225M | 294M | 283M | 315M | 383M | 507M | 730M |
| Gross Profit | 98.2M | 138M | 156M | 198M | 133M | 227M | 214M | 239M | 289M | 393M | 598M |
| Operating Income | 4.24M | -2.28M | -13.0M | -50.3M | -124M | -32.9M | -82.3M | -129M | -122M | -86.7M | -48.4M |
| EBITDA | 8.96M | 5.48M | -6.74M | -37.6M | -83.6M | -1.47M | -48.8M | -82.1M | -95.6M | -146M | 1.93M |
| Net Income | 4.52M | -92.0K | -13.0M | 15.4M | -120M | -49.6M | -99.2M | -135M | -146M | -188M | -48.2M |
| EPS | 0.12 | 0.00 | -0.37 | 0.37 | -2.70 | -1.07 | -2.09 | -2.78 | -2.77 | -3.28 | -0.79 |
| Balance Sheet | |||||||||||
| Total Assets | 134M | 166M | 207M | 818M | 1.01B | 1.13B | 1.07B | 940M | 975M | 893M | 980M |
| Total Liabilities | 17.1M | 27.6M | 33.1M | 145M | 338M | 542M | 544M | 479M | 208M | 237M | 262M |
| Shareholders' Equity | 117M | 138M | 174M | 673M | 667M | 587M | 530M | 462M | 767M | 656M | 717M |
| Cash & Short-term Investments | 95.8M | 119M | 140M | 174M | 404M | 414M | 353M | 295M | 319M | 279M | 337M |
| Total Debt | - | - | - | 72.6M | 272M | 383M | 383M | 384M | 103M | 140M | 102M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 12.3M | 25.5M | 18.9M | -369K | -23.0M | 24.7M | -33.1M | -57.8M | -61.3M | -46.3M | 54.5M |
| Capital Expenditure | 6.28M | 6.31M | 10.3M | 4.72M | 6.94M | 47.8M | 30.3M | 20.2M | 6.30M | 7.67M | 11.7M |
| Free Cash Flow | 6.03M | 19.2M | 8.55M | -5.09M | -29.9M | -23.1M | -63.3M | -78.0M | -67.6M | -54.0M | 42.8M |
| Ratios | |||||||||||
| ROE | 3.9% | -0.1% | -7.4% | 2.3% | -18.0% | -8.4% | -18.7% | -29.2% | -19.1% | -28.6% | -6.7% |
| ROA | 3.4% | -0.1% | -6.3% | 1.9% | -12.0% | -4.4% | -9.2% | -14.3% | -15.0% | -21.0% | -4.9% |
| Net Profit Margin | 4.0% | -0.1% | -7.1% | 6.5% | -53.5% | -16.9% | -35.1% | -42.8% | -38.2% | -37.0% | -6.6% |
| Debt to Equity | - | - | - | 0.11x | 0.41x | 0.65x | 0.72x | 0.83x | 0.13x | 0.21x | 0.14x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Glaukos Corp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 6.48M | 0.14 | - |
| 2021 | USD 27.3M | 0.59 | - |
| 2020 | USD 263M | 5.90 | - |
| 2019 | USD 12.9M | 0.31 | 83.3% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Glaukos Corp
- Insiders 4.09%
- Institutions 95.91%
- Public & others 0.00%
- Shares outstanding 59.2M
- Free float 57.0M
Top funds holding GKOS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 3.55M | 5.99% | -0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.78M | 3.00% | +0.27% | Sep 2026 |
| Vanguard Capital Opportunity Inv | 1.48M | 2.50% | +0.14% | Sep 2026 |
| iShares Russell 2000 ETF | 1.46M | 2.47% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 1.26M | 2.13% | -1.79% | Sep 2026 |
| PRIMECAP Odyssey Aggressive Growth | 1.00M | 1.69% | -1.17% | Sep 2026 |
| Janus Henderson Triton D | 996K | 1.68% | 0.00% | Sep 2026 |
| American Funds SMALLCAP World A | 989K | 1.67% | 0.00% | Sep 2026 |
| Janus Henderson Enterprise D | 709K | 1.20% | 0.00% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 702K | 1.19% | -4.68% | Sep 2026 |
| Janus Henderson Venture D | 642K | 1.08% | 0.00% | Sep 2026 |
| Janus Henderson Contrarian D | 639K | 1.08% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 631K | 1.07% | +0.14% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 542K | 0.92% | -0.38% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 539K | 0.91% | -0.05% | Oct 2026 |
| Fidelity Growth Company Fund | 481K | 0.81% | +1,145.60% | Aug 2026 |
| Invesco Discovery A | 467K | 0.79% | +10.04% | Sep 2026 |
| Nomura Small Cap Core I | 416K | 0.70% | 0.00% | Sep 2026 |
| PRIMECAP Odyssey Growth | 375K | 0.63% | +0.27% | Sep 2026 |
| Vanguard Tax-Managed Small Cap Adm | 373K | 0.63% | 0.00% | Sep 2026 |
Top institutions holding GKOS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 9.54M | 16.12% | +4.95% | Jun 2026 |
| Jupiter Topco LLC | 4.86M | 8.21% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.32M | 5.61% | +3.54% | Jun 2026 |
| PRIMECAP Management Company | 3.04M | 5.14% | -9.79% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.55M | 4.31% | +1.69% | Jun 2026 |
| State Street Corp | 2.32M | 3.91% | +6.09% | Jun 2026 |
| Millennium Management LLC | 1.58M | 2.67% | +34.70% | Jun 2026 |
| Holocene Advisors, LP | 1.51M | 2.56% | +9.48% | Jun 2026 |
| Geode Capital Management, LLC | 1.46M | 2.47% | +7.89% | Jun 2026 |
| Citadel Advisors Llc | 1.39M | 2.35% | -3.93% | Jun 2026 |
| Ameriprise Financial Inc | 1.32M | 2.22% | -18.36% | Jun 2026 |
| AllianceBernstein L.P. | 1.25M | 2.12% | -10.22% | Jun 2026 |
| Capital World Investors | 1.02M | 1.72% | +2.72% | Jun 2026 |
| The Goldman Sachs Group Inc | 897K | 1.52% | -34.76% | Jun 2026 |
| Charles Schwab Investment Management Inc | 753K | 1.27% | +5.35% | Jun 2026 |
| Amvescap Plc. | 707K | 1.19% | -22.68% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 680K | 1.15% | +102.02% | Jun 2026 |
| William Blair Investment Management, LLC | 662K | 1.12% | -38.38% | Jun 2026 |
| Driehaus Capital Management LLC | 651K | 1.10% | +33.34% | Jun 2026 |
| Delaware Management Holdings Inc | 647K | 1.09% | +5.78% | Jun 2026 |
Glaukos Corp company profile
- Company name
- Glaukos Corp
- Ticker
- GKOS.US
- Exchange
- USA Stocks
- Listed since
- Jun 25, 2015
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,094
- Fiscal year end
- December
- Address
- One Glaukos Way, Aliso Viejo, CA, United States, 92656
- Phone
- 949 367 9600
- Website
- glaukos.com
About Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Glaukos Corp management
10- Mr. Thomas William BurnsChairman & CEO · born 1961
- Mr. Joseph E. GilliamPresident & COO · born 1976
- Mr. Alex R. ThurmanSenior VP & CFO · born 1970
- Dr. Tomas Navratil Ph.D.Chief Development Officer · born 1977
- Mr. Christopher William LewisVice President of Investor Relations & Corporate Affairs
- Mr. Robert L. Davis J.D.Senior VP, General Counsel & Business Development · born 1966
- Ms. Diana A. SchererVP of Compliance & Deputy General Counsel
- Ms. Michele M. AllegrettoSenior Vice President of Human Resources
- Mr. L. Jay Katz FACS, M.D.Chief Medical Officer
- Dr. Gabriella Szekely Ph.D.Senior VP, Research & Development, Combination Pharmaceutical Products